Adam Bosak, MD
Pulmonary Disease · Glendale, AZNPI 1710115423
Payments from drug & device makers
Across 554 payments — averaging $161.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$40K
- Actelion Pharmaceuticals US, Inc.$37K
- AstraZeneca$6K
- Boehringer Ingelheim$1K
- Sanofi$915
- GSK$877
- plus $3K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 111 | $39,889 |
| Actelion Pharmaceuticals US, Inc. | 140 | $37,371 |
| AstraZeneca | 19 | $6,279 |
| Boehringer Ingelheim | 40 | $1,072 |
| Sanofi | 43 | $915 |
| GSK | 55 | $877 |
| Regeneron Healthcare Solutions, Inc. | 15 | $440 |
| Merck | 12 | $254 |
| Genentech USA, Inc. | 13 | $243 |
| Grifols USA, LLC | 9 | $240 |
| Advanced Respiratory, Inc | 11 | $217 |
| Inspire Medical Systems, Inc. | 3 | $182 |
| Novartis | 11 | $174 |
| Electromed, Inc. | 16 | $167 |
| CSL Behring | 5 | $150 |
| Baxter Healthcare | 7 | $143 |
| Philips North America LLC | 5 | $111 |
| Medtronic | 1 | $100 |
| Gilead | 4 | $92 |
| Insmed, Inc. | 5 | $84 |
| Boston Scientific | 4 | $77 |
| Amgen | 3 | $61 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Sunovion Pharmaceuticals Inc. | 3 | $57 |
| Circassia Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Inogen, Inc. | 2 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $33 |
| Pharming Healthcare, Inc. | 1 | $30 |
| Abbott | 2 | $29 |
| ZOLL Respicardia, Inc. | 1 | $24 |
| Springworks Therapeutics, Inc. | 1 | $22 |
| Sandoz | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| ADMA Biomanufacturing LLC | 1 | $17 |
| Pulmonx Corporation | 1 | $14 |
| Johnson & Johnson | 1 | $9 |
How this compares
$89,608 in reported general payments places this provider in the 85th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Glendale
- Muhammad SalimChandler$5.9M
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
- Rajat WaliaPhoenix$1.9M
- Robert OrrPeoria$1.6M
- Sachin ChaudharyTucson$1.2M
- Mark GotfriedPhoenix$1.1M
- George ParidesMesa$913K
- Richard SueGilbert$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.